In the news

Media mentions of NPLB & our board of directors

Congress is about to legislate a future without new medicines. We have a better plan.

Cutting investment into new medicines turns out to be no way to save.

BIOCENTURY: Investors, biopharma companies sound alarms on drug pricing legislation

"small biotechs that rely on venture capital...will disappear."

BIOCENTURY: Congress relying on flawed model to set drug pricing policy

CBO MODEL IGNORES IMPACT ON PRECLINICAL BIOTECHS

Aducanumab & the Alzheimer's Moonshot

What would it be worth to keep your mind?

A Glimpse into a Price-Controlled Future

What would it look like if some of the H.R. 3 bill's provisions were enacted?

Booker-Sanders-Harris drug affordability bureau could be brilliant

Or, it could completely collapse our industry

Insurance Reform, Not Executive Orders, is the Best Tool to Protect US Patients

The President's executive orders do nothing to lower out-of-pocket costs

Patients will be the losers as Pelosi's plan to control drug prices nearly strikes out

Two strikes and a home run

A quantum of innovation and the incentives to match

What's the smallest increment of medical innovation that is worth its cost to society?

If Trikafta Isn't Good Enough for ICER, What Drug Is?

A life-changing drug for cystic fibrosis patients is deemed "not worth it

We need a Public Domain Day to highlight when drugs go off patent

Let's celebrate when drug patents expire

Subscribe to our newsletter

Sign up for periodic updates about our work, healthcare saving tips, and how you can help make drugs affordable for every American